This HTML5 document contains 124 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
n19http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/pharmgkb/
n2http://linked.opendata.cz/resource/drugbank/drug/
dctermshttp://purl.org/dc/terms/
n30http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/kegg-compound/
n22http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/pdb/
n24http://linked.opendata.cz/resource/AHFS/
n12http://linked.opendata.cz/resource/mesh/concept/
foafhttp://xmlns.com/foaf/0.1/
n29http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/bindingdb/
n10http://linked.opendata.cz/resource/drugbank/company/
n20http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/pubchem-compound/
n9http://linked.opendata.cz/resource/drugbank/dosage/
n26http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/pubchem-substance/
n31http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/kegg-drug/
n32http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/drugbank/
n7http://bio2rdf.org/drugbank:
n21http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/national-drug-code-directory/
admshttp://www.w3.org/ns/adms#
n18http://www.rxlist.com/cgi/generic/
n25http://linked.opendata.cz/resource/drugbank/patent/
n17http://wifo5-03.informatik.uni-mannheim.de/drugbank/resource/drugs/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n28http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/chemspider/
n5http://linked.opendata.cz/resource/drugbank/medicinal-product/
owlhttp://www.w3.org/2002/07/owl#
n11http://linked.opendata.cz/ontology/mesh/
n3http://linked.opendata.cz/ontology/drugbank/
n16http://www.drugs.com/cdi/
n4http://linked.opendata.cz/resource/drugbank/property/
n27http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/chebi/
xsdhhttp://www.w3.org/2001/XMLSchema#
n14http://linked.opendata.cz/resource/drugbank/drug/DB00674/identifier/wikipedia/
n33http://linked.opendata.cz/resource/atc/
n23http://linked.opendata.cz/ontology/sukl/drug/

Statements

Subject Item
n2:DB00674
rdf:type
n3:Drug
n3:description
A benzazepine derived from norbelladine. It is found in galanthus and other amaryllidaceae. Galantamine is a cholinesterase inhibitor that has been used to reverse the muscular effects of gallamine triethiodide and tubocurarine, and has been studied as a treatment for Alzheimer's disease and other central nervous system disorders. [PubChem]
n3:dosage
n9:271B41A7-363D-11E5-9242-09173F13E4C5 n9:271B41A8-363D-11E5-9242-09173F13E4C5 n9:271B41A2-363D-11E5-9242-09173F13E4C5 n9:271B41A3-363D-11E5-9242-09173F13E4C5 n9:271B41A4-363D-11E5-9242-09173F13E4C5 n9:271B41A5-363D-11E5-9242-09173F13E4C5 n9:271B41A6-363D-11E5-9242-09173F13E4C5
n3:generalReferences
# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11129124 # Greenblatt HM, Kryger G, Lewis T, Silman I, Sussman JL: Structure of acetylcholinesterase complexed with (-)-galanthamine at 2.3 A resolution. FEBS Lett. 1999 Dec 17;463(3):321-6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/10606746 # Woodruff-Pak DS, Vogel RW 3rd, Wenk GL: Galantamine: effect on nicotinic receptor binding, acetylcholinesterase inhibition, and learning. Proc Natl Acad Sci U S A. 2001 Feb 13;98(4):2089-94. Epub 2001 Feb 6. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11172080 # Birks J: Cholinesterase inhibitors for Alzheimer's disease. Cochrane Database Syst Rev. 2006 Jan 25;(1):CD005593. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/16437532# Lilienfeld S: Galantamine--a novel cholinergic drug with a unique dual mode of action for the treatment of patients with Alzheimer's disease. CNS Drug Rev. 2002 Summer;8(2):159-76. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12177686 # Olin J, Schneider L: Galantamine for Alzheimer's disease. Cochrane Database Syst Rev. 2002;(3):CD001747. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/12137632# Scott LJ, Goa KL: Galantamine: a review of its use in Alzheimer's disease. Drugs. 2000 Nov;60(5):1095-122. "Pubmed":http://www.ncbi.nlm.nih.gov/pubmed/11129124
n3:group
approved
n3:halfLife
7 hours
n3:indication
For the treatment of mild to moderate dementia of the Alzheimer's type. Has also been investigated in patients with mild cognitive impairment who did not meet the diagnostic criteria for Alzheimer's disease.
n3:manufacturer
n10:271B418F-363D-11E5-9242-09173F13E4C5 n10:271B4190-363D-11E5-9242-09173F13E4C5 n10:271B418E-363D-11E5-9242-09173F13E4C5 n10:271B4193-363D-11E5-9242-09173F13E4C5 n10:271B4191-363D-11E5-9242-09173F13E4C5 n10:271B4192-363D-11E5-9242-09173F13E4C5 n10:271B4197-363D-11E5-9242-09173F13E4C5 n10:271B4195-363D-11E5-9242-09173F13E4C5 n10:271B4196-363D-11E5-9242-09173F13E4C5 n10:271B4194-363D-11E5-9242-09173F13E4C5 n10:271B4199-363D-11E5-9242-09173F13E4C5 n10:271B4198-363D-11E5-9242-09173F13E4C5
owl:sameAs
n7:DB00674 n17:DB00674
dcterms:title
Galantamine
adms:identifier
n14:Galantamine n19:PA449726 n20:908828 n21:0378-8104-91 n22:GNT n26:46505659 n27:5264 n28:23175565 n29:10404 n30:C08526 n31:D04292 n32:DB00674
n3:mechanismOfAction
Galantamine is a phenanthrene alkaloid and a reversible, competitive acetylcholinesterase inhibitor. It is not structurally related to other acetylcholinesterase inhibitors. Galantamine's proposed mechanism of action involves the reversible inhibition of acetylcholinesterase, which prevents the hydrolysis of acetycholine, leading to an increased concentration of acetylcholine at cholinergic synapses. Galantamine also binds allosterically with nicotinic acetylcholine receptors and may possibly potentiate the action of agonists (such as acetylcholine) at these receptors.
n3:packager
n10:271B4186-363D-11E5-9242-09173F13E4C5 n10:271B417D-363D-11E5-9242-09173F13E4C5 n10:271B417B-363D-11E5-9242-09173F13E4C5 n10:271B417C-363D-11E5-9242-09173F13E4C5 n10:271B4179-363D-11E5-9242-09173F13E4C5 n10:271B417A-363D-11E5-9242-09173F13E4C5 n10:271B4178-363D-11E5-9242-09173F13E4C5 n10:271B418D-363D-11E5-9242-09173F13E4C5 n10:271B418B-363D-11E5-9242-09173F13E4C5 n10:271B418C-363D-11E5-9242-09173F13E4C5 n10:271B4189-363D-11E5-9242-09173F13E4C5 n10:271B418A-363D-11E5-9242-09173F13E4C5 n10:271B4187-363D-11E5-9242-09173F13E4C5 n10:271B4188-363D-11E5-9242-09173F13E4C5 n10:271B4184-363D-11E5-9242-09173F13E4C5 n10:271B4185-363D-11E5-9242-09173F13E4C5 n10:271B4182-363D-11E5-9242-09173F13E4C5 n10:271B4183-363D-11E5-9242-09173F13E4C5 n10:271B4180-363D-11E5-9242-09173F13E4C5 n10:271B4181-363D-11E5-9242-09173F13E4C5 n10:271B417E-363D-11E5-9242-09173F13E4C5 n10:271B417F-363D-11E5-9242-09173F13E4C5 n10:271B4176-363D-11E5-9242-09173F13E4C5 n10:271B4177-363D-11E5-9242-09173F13E4C5
n3:patent
n25:6099863 n25:2310926 n25:2358062 n25:7160559
n3:routeOfElimination
Galantamine is metabolized by hepatic cytochrome P450 enzymes, glucuronidated, and excreted unchanged in the urine.
n3:synonym
Galanthamine (-)-Galanthamine
n3:toxicity
LD<sub>50</sub>=75 mg/kg (rat)
n3:volumeOfDistribution
* 175 L
n23:hasAHFSCode
n24:12-04-00
n3:foodInteraction
Take with food.
n3:proteinBinding
18%
n3:salt
n3:synthesisReference
Vijaya Bolugoddu, Sanjay Shukla, Mukunda Jambula, Rajeshwar Sagyam, Ramchandra Pingili, Ananda Thirunavakarasu, "Preparation of (-)-galantamine hydrobromide." U.S. Patent US20060009640, issued January 12, 2006.
n11:hasConcept
n12:M0008951
foaf:page
n16:galantamine.html n18:reminyl.htm
n3:IUPAC-Name
n4:271B41AD-363D-11E5-9242-09173F13E4C5
n3:InChI
n4:271B41B3-363D-11E5-9242-09173F13E4C5
n3:Molecular-Formula
n4:271B41B2-363D-11E5-9242-09173F13E4C5
n3:Molecular-Weight
n4:271B41AF-363D-11E5-9242-09173F13E4C5
n3:Monoisotopic-Weight
n4:271B41B0-363D-11E5-9242-09173F13E4C5
n3:SMILES
n4:271B41B1-363D-11E5-9242-09173F13E4C5
n3:Water-Solubility
n4:271B41AB-363D-11E5-9242-09173F13E4C5 n4:271B41C3-363D-11E5-9242-09173F13E4C5
n3:logP
n4:271B41AC-363D-11E5-9242-09173F13E4C5 n4:271B41C5-363D-11E5-9242-09173F13E4C5 n4:271B41A9-363D-11E5-9242-09173F13E4C5
n3:logS
n4:271B41AA-363D-11E5-9242-09173F13E4C5
n23:hasATCCode
n33:N06DA04
n3:H-Bond-Acceptor-Count
n4:271B41B9-363D-11E5-9242-09173F13E4C5
n3:H-Bond-Donor-Count
n4:271B41BA-363D-11E5-9242-09173F13E4C5
n3:InChIKey
n4:271B41B4-363D-11E5-9242-09173F13E4C5
n3:Polar-Surface-Area--PSA-
n4:271B41B5-363D-11E5-9242-09173F13E4C5
n3:Polarizability
n4:271B41B7-363D-11E5-9242-09173F13E4C5
n3:Refractivity
n4:271B41B6-363D-11E5-9242-09173F13E4C5
n3:Rotatable-Bond-Count
n4:271B41B8-363D-11E5-9242-09173F13E4C5
n3:affectedOrganism
Humans and other mammals
n3:casRegistryNumber
357-70-0
n3:category
n3:clearance
* 300 mL/min [After IV. or oral administration]
n3:containedIn
n5:271B419A-363D-11E5-9242-09173F13E4C5 n5:271B419B-363D-11E5-9242-09173F13E4C5 n5:271B41A0-363D-11E5-9242-09173F13E4C5 n5:271B41A1-363D-11E5-9242-09173F13E4C5 n5:271B419E-363D-11E5-9242-09173F13E4C5 n5:271B419F-363D-11E5-9242-09173F13E4C5 n5:271B419C-363D-11E5-9242-09173F13E4C5 n5:271B419D-363D-11E5-9242-09173F13E4C5
n3:Bioavailability
n4:271B41BF-363D-11E5-9242-09173F13E4C5
n3:Ghose-Filter
n4:271B41C1-363D-11E5-9242-09173F13E4C5
n3:MDDR-Like-Rule
n4:271B41C2-363D-11E5-9242-09173F13E4C5
n3:Melting-Point
n4:271B41C4-363D-11E5-9242-09173F13E4C5
n3:Number-of-Rings
n4:271B41BE-363D-11E5-9242-09173F13E4C5
n3:Physiological-Charge
n4:271B41BD-363D-11E5-9242-09173F13E4C5
n3:Rule-of-Five
n4:271B41C0-363D-11E5-9242-09173F13E4C5
n3:Traditional-IUPAC-Name
n4:271B41AE-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-acidic-
n4:271B41BB-363D-11E5-9242-09173F13E4C5
n3:pKa--strongest-basic-
n4:271B41BC-363D-11E5-9242-09173F13E4C5